| Literature DB >> 24650243 |
Ulrike Dapunt1, Thomas Giese, Felix Lasitschka, Jörn Reinders, Burkhard Lehner, Jan Philippe Kretzer, Volker Ewerbeck, Gertrud Maria Hänsch.
Abstract
BACKGROUND: Metal-on-metal implants are a special form of hip endoprostheses that despite many advantages can entail serious complications due to release of wear particles from the implanted material. Metal wear particles presumably activate local host defence mechanisms, which causes a persistent inflammatory response with destruction of bone followed by a loosening of the implant. To better characterize this inflammatory response and to link inflammation to bone degradation, the local generation of proinflammatory and osteoclast-inducing cytokines was analysed, as was systemic T cell activation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24650243 PMCID: PMC3994416 DOI: 10.1186/1479-5876-12-74
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Figure 1Clinical and histological images. A Shown are x-rays of a patient with a metal-on-metal hip resurfacing implant (left) and on the right of a patient with a total hip joint replacement. B After the removal of the implant, deposition of metal particles is seen as is the formation of a pseudotumour (arrow). C The removed implants are shown; they are "empty" due to bone loss. D, E Biopsies from an osteolytic site show infiltration of leukocytes, particularly of mononuclear cells, and deposits of metal wear particles.
Patients’ clinical and laboratory findings ( metallosis and aseptic loosening)
| | | ||||||
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| 1 | 62 | Pain, osteolysis around cup on x-ray | a) 21.3 μg/L | 2.3 mg/L | 4.55/nl | 8 | Metal on metal |
| | b) 37.6 μg/L | | |||||
| 2 | 47 | Pain | a) 17.7 μg/L | 16.6 mg/L | 8.96/nl | 5 | Metal on metal |
| | b) 38.90 μg/L | | |||||
| 3 | 42 | Pain | a) 4.06 μg/L | 3.6 mg/L | 9.39/nl | 6 | Metal on metal |
| | b) 5.49 μg/L | | |||||
| 4 | 71 | Pain | a) 15.0ug/L | 6.9 mg/L | 5.89/nl | 6 | Metal on metal |
| | b) 30.0ug/L | | |||||
| 5 | 60 | Non | a) 43.0 μg/L | 2.0 mg/L | 5.70/nl | 8 | Metal on metal |
| | b) 64.0 μg/L | | |||||
| | | | | ||||
| 1 | 70 | Pain, osteolysis around cup and stem on x-ray | 17.3 mg/l | 4.91/nl | 19 | Ceramic on polyethylene | |
| 2 | 71 | Pain, osteolysis around stem on x-ray | 10.0 mg/l | 8.17/nl | 3 | Ceramic on polyethylene | |
| 3 | 75 | Pain, osteolysis around cup on x-ray | 2.0 mg/l | 5.74/nl | 15 | Metal on polyethylene | |
| 4 | 59 | Pain, osteolysis around stem on x-ray | 2.0 mg/l | 3.53/nl | 2 | Ceramic on polyethylene | |
| 5 | 81 | Pain, osteolysis around stem on x-ray | 2.0 mg/l | 6.92/nl | 12 | Metal on polyethylene | |
| 6 | 84 | Pain, osteolysis around stem on x-ray | 2.0 mg/l | 6.1/nl | 6 | Metal on polyethylene | |
Metal ions were measured pre-operatively as indicator of increased wear debris.
CRP levels and white cell count were measured pre-operatively as signs of infection.
Figure 2Expression of cathepsin K, CD14, CD3 and of proinflammtory cytokines in tissue derived from the cup or the muscle: cytokine expression was determined by RT-PCR and quantified as number of transcripts. Data of 5 patients (each symbol represent one patients) with metallosis are shown.
Gene expression of cathepsin K, CD3, CD14 and of cytokines in tissue of patients with metallosis
| Cathepsin K | 2603.0 ± 1220.8* | 968.4 ± 392.4 | n.d. |
| CD3 | 288.6 ± 262.2 | 42.2 ± 26.4 | p = 0.036 |
| CD14 | 1806.2 ± 1211.9 | 334.2 ± 247.7 | p = 0.012 |
| CXCL8 | 677.0 ± 355.5 | 27.0 ± 20.8 | p = 0.043 |
| IL1ß | 101.4 ± 90.7 | 9.0 ± 3.5 | p = 0.043 |
| CXCL2 | 276.5 ± 125.0 | 92.8 ± 51.5 | p = 0.040 |
| MRP14 | 82376.8 ± 78340.0 | 377.4 ± 396.0 | p = 0.040 |
| RANK | 10.9 ± 9.8 | 8.2 ± 5.7 | n.d. |
| RANKL | 4.1 ± 4.0 | 0.2 ± 0.2 | n.d. |
| TNFα | 11.5 ± 4.0 | 7.3 ± 1.0 | n.d. |
| CXCL10 | 184.7 ± 239.5 | 131.6 ± 147.8 | n.d. |
| CCL2 | 1612.1 ± 1958.9 | 652.0 ± 144.8 | n.d. |
*copy number; n.d. = not different.
Cytokine expression in tissue of patients with metallosis versus aseptic loosening
| | ||||||
|---|---|---|---|---|---|---|
| | | | ||||
| CXCL8 | 106.2 ± 106.6 | 379.2 ± 494.1 | 181.3 ± 305.4 | |||
| IL-1 | 11.2 ± 12.1 | 47.9 ± 48.4 | 12.2 ± 18.8 | |||
| RANK | 5.6 ± 5.9 | 9.5 ± 8.8 | 11 ± 4.5 | 26.3 ± 32.7 | 8.2 ± 5.7 | 19.3 ± 22.9 |
| RANKL | 4.4 ± 7 | 17.3 ± 18.7 | 11 ± 8.2 | 44.7 ± 50.2 | 0.2 ± 0.4 | 2 ± 4.9 |
| Cathepsin K | 2708.8 ± 2139.7 | 4794.9 ± 2817.2 | 3313.3 ± 1646.1 | 6871.6 ± 4937.7 | 968.4 ± 392.4 | 2958.5 ± 3390.7 |
| CCL2 | 2005.7 ± 1321.5 | 990.7 ± 512.6 | 3439.8 ± 2892.6 | 1196.3 ± 575.3 | 652 ± 144.8 | 1065.8 ± 1030.5 |
| CD14 | 823.8 ± 488.9 | 687.8 ± 417.2 | ||||
| CD3 | 64.1 ± 59.8 | 29.5 ± 15.7 | 111.5 ± 77.1 | 62.2 ± 69.9 | 42.2 ± 26.5 | 45.7 ± 19.3 |
| TNFα | 10.6 ± 10 | 3.7 ± 2.2 | 12.8 ± 7 | 5.7 ± 3.7 | 5.8 ± 3.3 | 4.2 ± 6.2 |
| CXCL10 | 25.9 ± 17.6 | 41.7 ± 26.9 * | 131.6 ± 147.8 | 607.2 ± 1167.8 | ||
| MRP14 | 377.4 ± 396 | 2186.7 ± 2080.3 | ||||
| CXCL2 | 670 ± 635.2 | 133.8 ± 100.2 | 92.8 ± 51.6 | 262.3 ± 467.9 | ||
The bold print indicates that the groups differ significantly as tested by Mann–Whitney test; * indicates differences between metallosis and aseptic loosening; the + differences between capsule/femoral bone tissue and muscle.
Figure 3Cytofluorometry of peripheral T cells. A By cytofluorometry the peripheral T cells of a patient before and 9 days after surgery were analysed. Before surgery, 57.0% of CD8+ cells were negative for CD28, but only 45.6% after surgery; and 7.4% of CD4 versus 4.6% after surgery. The CD8 + CD28- and CD4 + CD28- cells expressed CD11b, indicative of an activated T effector cell. B Shown is the percentage of CD4 + CD28- cells in patients with metallosis (left) or patients with aseptic loosening (right) before and after surgery. C The mean fluorescence intensity of CD11b on T cells declined after surgery (shown are data of four patients; each symbol refers to one patient and data obtained before and after surgery are connected by a line).